Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.26%AUDUSD-1.13%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.83%GBPCAD+0.79%USDCAD+0.66%EURGBP-0.66%GBPNZD+0.65%EURAUD+0.62%AUDNZD-0.60%USDTHB+0.58%CHFJPY-0.54%NZDUSD-0.53%EURUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.40%CADJPY-0.39%GBPHKD+0.32%AUDCHF-0.32%NZDCHF+0.31%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%EURJPY-0.27%USDJPY+0.25%NZDJPY-0.25%USDCNH-0.19%CADCHF+0.18%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%GBPUSD+0.14%EURCAD+0.13%NZDCAD+0.13%EURZAR+0.10%USDZAR+0.09%GBPZAR+0.09%CHFNOK+0.08%EURNOK+0.05%USDCOP-0.04%EURCZK-0.04%CHFSEK+0.04%CHFSGD+0.04%USDHKD+0.04%AUDNOK+0.04%USDMXN+0.03%USDNOK+0.03%EURPLN+0.02%NZDMXN+0.02%USDDKK-0.02%AUDDKK-0.02%EURNZD+0.02%EURCNH+0.02%USDSEK-0.01%EURSGD+0.01%USDPLN+0.01%EURSEK+0.01%GBPSGD0.00%EURHKD0.00%EURDKK0.00%USDSGD0.00%AUDSGD0.00%NZDSGD0.00%XPTUSD-0.88%GAGUSD-0.55%XAGUSD-0.55%HG1-0.37%W1+0.31%GAUUSD-0.28%XAUUSD-0.28%XNGUSD+0.21%UKOIL+0.16%S1-0.13%C1+0.13%USOIL+0.02%BTCUSD-0.23%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.10%ZECUSDT+0.54%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.54%XLMUSD+1.65%BCHUSDT-0.58%UNIUSD-0.31%LTCUSD+0.07%HBARUSDT+2.14%SUIUSD+0.84%TONUSD+15.77%TAOUSDT+0.14%AAVEUSD-3.72%DOTUSDT+2.53%ICPUSDT-3.35%ONDOUSDT-0.32%WLDUSDT+10.71%ARBUSDT-0.49%JUPUSDT-0.20%ATOMUSDT+1.04%INJUSDT-2.78%STXUSDT+17.38%FETUSDT+1.99%SEIUSDT+0.33%PYTHUSDT-2.32%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT-0.04%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.43%POLUSDT-4.36%AXSUSDT+0.76%FARTCOINUSDT-0.45%EOSUSDT+4.55%DYDXUSDT+3.32%GALAUSDT+4.30%ORDIUSDT+1.19%NOTUSDT+1.55%RONINUSDT+0.85%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.26%AUDUSD-1.13%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.83%GBPCAD+0.79%USDCAD+0.66%EURGBP-0.66%GBPNZD+0.65%EURAUD+0.62%AUDNZD-0.60%USDTHB+0.58%CHFJPY-0.54%NZDUSD-0.53%EURUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.40%CADJPY-0.39%GBPHKD+0.32%AUDCHF-0.32%NZDCHF+0.31%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%EURJPY-0.27%USDJPY+0.25%NZDJPY-0.25%USDCNH-0.19%CADCHF+0.18%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%GBPUSD+0.14%EURCAD+0.13%NZDCAD+0.13%EURZAR+0.10%USDZAR+0.09%GBPZAR+0.09%CHFNOK+0.08%EURNOK+0.05%USDCOP-0.04%EURCZK-0.04%CHFSEK+0.04%CHFSGD+0.04%USDHKD+0.04%AUDNOK+0.04%USDMXN+0.03%USDNOK+0.03%EURPLN+0.02%NZDMXN+0.02%USDDKK-0.02%AUDDKK-0.02%EURNZD+0.02%EURCNH+0.02%USDSEK-0.01%EURSGD+0.01%USDPLN+0.01%EURSEK+0.01%GBPSGD0.00%EURHKD0.00%EURDKK0.00%USDSGD0.00%AUDSGD0.00%NZDSGD0.00%XPTUSD-0.88%GAGUSD-0.55%XAGUSD-0.55%HG1-0.37%W1+0.31%GAUUSD-0.28%XAUUSD-0.28%XNGUSD+0.21%UKOIL+0.16%S1-0.13%C1+0.13%USOIL+0.02%BTCUSD-0.23%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.10%ZECUSDT+0.54%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.54%XLMUSD+1.65%BCHUSDT-0.58%UNIUSD-0.31%LTCUSD+0.07%HBARUSDT+2.14%SUIUSD+0.84%TONUSD+15.77%TAOUSDT+0.14%AAVEUSD-3.72%DOTUSDT+2.53%ICPUSDT-3.35%ONDOUSDT-0.32%WLDUSDT+10.71%ARBUSDT-0.49%JUPUSDT-0.20%ATOMUSDT+1.04%INJUSDT-2.78%STXUSDT+17.38%FETUSDT+1.99%SEIUSDT+0.33%PYTHUSDT-2.32%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT-0.04%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.43%POLUSDT-4.36%AXSUSDT+0.76%FARTCOINUSDT-0.45%EOSUSDT+4.55%DYDXUSDT+3.32%GALAUSDT+4.30%ORDIUSDT+1.19%NOTUSDT+1.55%RONINUSDT+0.85%
RM

Revolution Medicines, Inc. (RVMD)

NASDAQ • Healthcare

$205.26
+$0.78 (+0.4%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$205.48
Day Range$203 - $209.79
Avg. Volume (3M)2M
Market Cap$43.6B
52 Week Range
$45.61$224.31
Next EarningsIn 34 daysNov 4, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$1.7B
EPS (TTM)
-$8.86
ROA (TTM)
-40.9%
Current Ratio
11.38

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-17.7%Q1 2026-$1.86
-24.5%Q2 2026-$2.29
-50.0%Q3 2026-$3.06
Next

Nov 4

in 34 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -50.0%

Based on preliminary results, Revolution Medicines’ fiscal second quarter of 2026, reported Aug. 5, showed a wider-than-expected loss: EPS of -$3.06 missed the -$2.04 estimate by 50%, versus -$1.31 a year ago. Net loss widened to about $644.4 million from $247.8 million a year earlier, and operating loss came in at roughly $505.1 million. Operating cash flow was negative $741.5 million, reflecting the cash burn in the period. Gross profit was $0.00. The company also guided to next-period consensus EPS of -$2.02 on revenue of $10.2 million.

View full earnings history

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage precision oncology biotechnology company listed on NASDAQ as RVMD. The company develops targeted cancer medicines aimed at pathways central to RAS-driven tumors, and its work centers on a pipeline of inhibitors designed for specific signaling proteins and mutation states rather than marketed products.

Name
Revolution Medicines, Inc.
CEO
Mark A. Goldsmith
Website
www.revmed.com
Industry
Healthcare
Year Founded
2014
Employees
883

Today's Snapshot

AI-generated

RVMD ended the day slightly higher at 205.26, while its sector was weaker.

Trading Volume

Below 10d avg (2.6M)

1.8M

vs S&P 500 Today

Moderate Outperformance

+0.19%

Updated: September 30, 2026 at 20:19 UTC

RVMD Headlines

Tom Steyer backs select biotech names

May 2, 2026

3 min read
View All News

Technical Indicators

5 Buy3 Neutral0 Sell
RVMD is trading just above its classic pivot and a cluster of short- to long-term moving averages, reflecting that recent gains are broadly supported by trend-following measures while the ADX indicates the trend lacks strength. Momentum measures show slight upside, with the 10-period momentum positive and oscillators around neutral, and MACD near flat, suggesting constructive but modest buying pressure. Volatility is moderate given the ATR, and on-balance volume is favorable, which supports the price advance. Technical takeaway: Mild buy—price action is bullish versus key averages but trend strength remains limited.
All signals
  • EMA (5 indicators)$146.22 - $201.63
    Buy
  • RSI (14)54.44
    Neutral
  • Stochastic %K (14, 3, 3)65.90
    Neutral
  • MACD Level (12, 26)-0.45
    Neutral

Peers & Related Assets

MRNAModerna, Inc.
$192.57-5.3%
ROIVRoivant Sciences Ltd.
$36.57+0.2%
EXELExelixis, Inc.
$58.41-0.4%
SMMTSummit Therapeutics Inc.
$16.91+3.2%
BBIOBridgeBio Pharma, Inc.
$65.8-0.3%
MDGLMadrigal Pharmaceuticals, Inc.
$503.96-1.1%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.